Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Trial Profile

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms CEDAR
  • Most Recent Events

    • 28 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 18 Feb 2016 Planned initiation date changed from 1 Jan 2016 to 1 May 2016, according to ClinicalTrials.gov record.
    • 11 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top